LRP4
Low-density lipoprotein receptor-related protein 4
Also known as: CLSS, LRP-4, LRP4_HUMAN, MEGF7, SOST2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O75096
- Gene
- LRP4
- Ensembl
- ENSG00000134569
- Chromosome
- 11
- Canonical length
- 1905 aa
- Protein class
- Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters
- Subcellular location
- Nucleoplasm,Mitochondria
- Quaternary structure
- Homooligomer
OverviewNCBI Gene
This gene encodes a member of the low-density lipoprotein receptor-related protein family. The encoded protein may be a regulator of Wnt signaling. Mutations in this gene are associated with Cenani-Lenz syndrome. [provided by RefSeq, May 2010]
Canonical amino-acid sequenceUniProt
1905 residues, UniProt reviewed canonical sequence.
>O75096|LRP4
1 MRRQWGALLL GALLCAHGLA SSPECACGRS HFTCAVSALG ECTCIPAQWQ CDGDNDCGDH
61 SDEDGCILPT CSPLDFHCDN GKCIRRSWVC DGDNDCEDDS DEQDCPPREC EEDEFPCQNG
121 YCIRSLWHCD GDNDCGDNSD EQCDMRKCSD KEFRCSDGSC IAEHWYCDGD TDCKDGSDEE
181 NCPSAVPAPP CNLEEFQCAY GRCILDIYHC DGDDDCGDWS DESDCSSHQP CRSGEFMCDS
241 GLCINAGWRC DGDADCDDQS DERNCTTSMC TAEQFRCHSG RCVRLSWRCD GEDDCADNSD
301 EENCENTGSP QCALDQFLCW NGRCIGQRKL CNGVNDCGDN SDESPQQNCR PRTGEENCNV
361 NNGGCAQKCQ MVRGAVQCTC HTGYRLTEDG HTCQDVNECA EEGYCSQGCT NSEGAFQCWC
421 ETGYELRPDR RSCKALGPEP VLLFANRIDI RQVLPHRSEY TLLLNNLENA IALDFHHRRE
481 LVFWSDVTLD RILRANLNGS NVEEVVSTGL ESPGGLAVDW VHDKLYWTDS GTSRIEVANL
541 DGAHRKVLLW QNLEKPRAIA LHPMEGTIYW TDWGNTPRIE ASSMDGSGRR IIADTHLFWP
601 NGLTIDYAGR RMYWVDAKHH VIERANLDGS HRKAVISQGL PHPFAITVFE DSLYWTDWHT
661 KSINSANKFT GKNQEIIRNK LHFPMDIHTL HPQRQPAGKN RCGDNNGGCT HLCLPSGQNY
721 TCACPTGFRK ISSHACAQSL DKFLLFARRM DIRRISFDTE DLSDDVIPLA DVRSAVALDW
781 DSRDDHVYWT DVSTDTISRA KWDGTGQEVV VDTSLESPAG LAIDWVTNKL YWTDAGTDRI
841 EVANTDGSMR TVLIWENLDR PRDIVVEPMG GYMYWTDWGA SPKIERAGMD ASGRQVIISS
901 NLTWPNGLAI DYGSQRLYWA DAGMKTIEFA GLDGSKRKVL IGSQLPHPFG LTLYGERIYW
961 TDWQTKSIQS ADRLTGLDRE TLQENLENLM DIHVFHRRRP PVSTPCAMEN GGCSHLCLRS
1021 PNPSGFSCTC PTGINLLSDG KTCSPGMNSF LIFARRIDIR MVSLDIPYFA DVVVPINITM
1081 KNTIAIGVDP QEGKVYWSDS TLHRISRANL DGSQHEDIIT TGLQTTDGLA VDAIGRKVYW
1141 TDTGTNRIEV GNLDGSMRKV LVWQNLDSPR AIVLYHEMGF MYWTDWGENA KLERSGMDGS
1201 DRAVLINNNL GWPNGLTVDK ASSQLLWADA HTERIEAADL NGANRHTLVS PVQHPYGLTL
1261 LDSYIYWTDW QTRSIHRADK GTGSNVILVR SNLPGLMDMQ AVDRAQPLGF NKCGSRNGGC
1321 SHLCLPRPSG FSCACPTGIQ LKGDGKTCDP SPETYLLFSS RGSIRRISLD TSDHTDVHVP
1381 VPELNNVISL DYDSVDGKVY YTDVFLDVIR RADLNGSNME TVIGRGLKTT DGLAVDWVAR
1441 NLYWTDTGRN TIEASRLDGS CRKVLINNSL DEPRAIAVFP RKGYLFWTDW GHIAKIERAN
1501 LDGSERKVLI NTDLGWPNGL TLDYDTRRIY WVDAHLDRIE SADLNGKLRQ VLVSHVSHPF
1561 ALTQQDRWIY WTDWQTKSIQ RVDKYSGRNK ETVLANVEGL MDIIVVSPQR QTGTNACGVN
1621 NGGCTHLCFA RASDFVCACP DEPDSRPCSL VPGLVPPAPR ATGMSEKSPV LPNTPPTTLY
1681 SSTTRTRTSL EEVEGRCSER DARLGLCARS NDAVPAAPGE GLHISYAIGG LLSILLILVV
1741 IAALMLYRHK KSKFTDPGMG NLTYSNPSYR TSTQEVKIEA IPKPAMYNQL CYKKEGGPDH
1801 NYTKEKIKIV EGICLLSGDD AEWDDLKQLR SSRGGLLRDH VCMKTDTVSI QASSGSLDDT
1861 ETEQLLQEEQ SECSSVHTAA TPERRGSLPD TGWKHERKLS SESQVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LRP4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 30 nTPM
Expression across tissuesHPA
Tissue
- skin: 30 nTPM
- cerebral cortex: 19 nTPM
- basal ganglia: 17 nTPM
- amygdala: 10 nTPM
- hippocampal formation: 7.7 nTPM
- stomach: 7.4 nTPM
Single-cell type
- pituicytes/fscs: 306 nCPM
- oligodendrocyte progenitor cells: 215 nCPM
- cone photoreceptor cells: 201 nCPM
- astrocytes: 168 nCPM
- papillary tip epithelial cells: 111 nCPM
- bergmann glia: 111 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- medulla oblongata: 131 nTPM
- thalamus: 95 nTPM
- basal ganglia: 93 nTPM
- white matter: 84 nTPM
- hippocampal formation: 81 nTPM
- amygdala: 80 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about LRP4.
Disease | AllUniProt
Conditions LRP4 is implicated in, by any mechanism.
- Cenani-Lenz syndactyly syndrome (CLSS) MIM:212780
- Sclerosteosis 2 (SOST2) MIM:614305
- Myasthenic syndrome, congenital, 17 (CMS17) MIM:616304
Disease | GeneticClinVar
49 pathogenic / likely-pathogenic of 1,543 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Cenani-Lenz syndactyly syndrome
- Congenital myasthenic syndrome 17
- Sclerosteosis 2
- LRP4-related disorder
- Isolated hand syndactyly
Disease | AutoantibodyPubMed
Conditions in which antibodies against LRP4 are reported. Each links to that disease's full target list.
Showing 2 of 3 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for LRP4 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
60 publications
- Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.
2011 · Ann Neurol · RCR 10.5 · 353 citations - Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
2025 · Lancet Neurol · RCR 10.4 · 28 citations - The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes.
2013 · Autoimmun Rev · RCR 8.9 · 269 citations - A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.
2014 · J Autoimmun · RCR 8.6 · 232 citations - Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
2012 · J Neurol · RCR 7.5 · 244 citations
Show 20 more of 60 total
- Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.
2012 · Arch Neurol · RCR 7.4 · 234 citations - Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.
2013 · J Clin Invest · RCR 4.9 · 157 citations - Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis.
2015 · JAMA Neurol · RCR 4.6 · 113 citations - Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis.
2022 · J Neurol Neurosurg Psychiatry · RCR 4.3 · 43 citations - MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
2013 · PLoS One · RCR 4.2 · 130 citations - Autoantibodies to agrin in myasthenia gravis patients.
2014 · PLoS One · RCR 4 · 113 citations - Functional Signature of LRP4 Antibodies in Myasthenia Gravis.
2024 · Neurol Neuroimmunol Neuroinflamm · RCR 3.6 · 15 citations - LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients.
2014 · Ann Clin Transl Neurol · RCR 3.2 · 90 citations - Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.
2016 · JAMA Neurol · RCR 3.1 · 68 citations - Myasthenia gravis: Molecular mechanisms and promising therapeutic strategies.
2023 · Biochem Pharmacol · RCR 3 · 24 citations - LRP4-IgG service line testing in seronegative myasthenia gravis and controls.
2022 · J Neuroimmunol · RCR 2.1 · 20 citations - Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen.
2016 · J Neuroimmunol · RCR 2.1 · 47 citations - Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis.
2019 · Eur J Neurol · RCR 2 · 29 citations - Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients.
2017 · Muscle Nerve · RCR 1.9 · 44 citations - Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case-Control study.
2022 · Front Neurol · RCR 1.7 · 11 citations - Autoimmune mechanisms in myasthenia gravis.
2012 · Curr Opin Neurol · RCR 1.6 · 57 citations - Improving laboratory diagnostics in myasthenia gravis.
2021 · Expert Rev Mol Diagn · RCR 1.4 · 18 citations - Synaptic plasticity and cognitive function are disrupted in the absence of Lrp4.
2014 · Elife · RCR 1.3 · 42 citations - Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis.
2015 · PLoS One · RCR 1.3 · 31 citations - Myasthenia gravis and related disorders: Pathology and molecular pathogenesis.
2015 · Biochim Biophys Acta · RCR 1.3 · 40 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.42
- gnomAD pLI
- 0
- gnomAD missense Z
- 3.06
- DepMap mean gene effect
- -0.16
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- amyloid-beta clearance by cellular catabolic process
- dendrite morphogenesis
- dorsal/ventral pattern formation
- embryonic digit morphogenesis
- endocytosis
- enzyme-linked receptor protein signaling pathway
- generation of neurons
- hair follicle development
- kidney development
- limb development
- negative regulation of axonogenesis
- negative regulation of canonical Wnt signaling pathway
- negative regulation of ossification
- odontogenesis of dentin-containing tooth
- positive regulation of Rac protein signal transduction
- positive regulation of skeletal muscle acetylcholine-gated channel clustering
- postsynaptic membrane assembly
- presynaptic membrane assembly
- proximal/distal pattern formation
- Rac protein signal transduction
- regulation of postsynapse assembly
- skeletal muscle acetylcholine-gated channel clustering
- synapse organization
- synaptic assembly at neuromuscular junction
- Wnt signaling pathway
- positive regulation of presynaptic membrane organization
Molecular functions
- apolipoprotein binding
- calcium ion binding
- coreceptor activity
- protein homodimerization activity
- receptor tyrosine kinase binding
- scaffold protein binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- LDLR class B repeat
- EGF-like domain
- EGF-like calcium-binding domain
- Low-density lipoprotein (LDL) receptor class A repeat
- Growth factor receptor cysteine-rich domain superfamily
- Six-bladed beta-propeller, TolB-like
- EGF-like calcium-binding, conserved site
- Low-density lipoprotein (LDL) receptor class A, conserved site
- Complement Clr-like EGF domain
- LDL receptor-like superfamily
- Low-density lipoprotein receptor-related
- Low-density lipoprotein receptor domain class A
- Low-density lipoprotein receptor repeat class B
- Complement Clr-like EGF-like
- Coagulation Factor Xa inhibitory site
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of LRP4 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LRP4 as an antibody target. Whether an autoantibody or antibody against LRP4 could matter depends on whether native LRP4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LRP4 is annotated at the cell surface, where native LRP4 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LRP4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...